Volume 3, Issue 11, 03/15/2011
Why are rheumatoid arthritis patients with CYP1A2*1F genetic polymorphism at an increased risk for leflunomide (Arava) toxicity?
The cytochrome P450 (CYP) 1A2 enzyme is a well known phase I pathway for drug metabolism and/or elimination. As with many enzymes in the human body, its activity can be influenced by genetic polymorphisms or variations in the genetic code that make the CYP1A2 enzyme. While most CYP1A2 genetic polymorphisms are thought to be associated with...
.......To read the full answer please LOGIN or SUBSCRIBE NOW.
Copyright 2012 Pharmacology Weekly, Inc. All Rights Reserved. |
